Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Yusuke FunakoshiNobuhiro HataKosuke TakigawaHideyuki AritaDaisuke KugaRyusuke HataeYuhei SangatsudaYutaka FujiokaAki SakoToru UmeharaTadamasa YoshitakeOsamu TogaoAkio HiwatashiKoji YoshimotoToru IwakiMasahiro MizoguchiPublished in: Cancer medicine (2021)
MGMT and CDKN2A status subdivided our cohort into three race-specific groups with different prognoses. Our findings indicate that BEV approval in Japan led to OS improvement exclusively for patients with concurrent unmethylated MGMT status and CDKN2A homozygous deletion.